Dynamic Monitoring of Activation of G-Protein Coupled Receptor (GPCR) and Receptor Tyrosine Kinase (RTK) in Living Cells Using Real-Time Microelectronic Cell Sensing Technology
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application 61/191,684, filed Sep 11, 2008. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,263,375 | Dynamic Monitoring of Activation of G-Protein Coupled Receptor (GPCR) and Receptor Tyrosine Kinase (RTK) in Living Cells Using Real-Time Microelectronic Cell Sensing Technology In force · High confidence | Agilent Technologies, Inc. | In force | High confidence | ||
| US 10,012,636 | Label-Free Monitoring of Excitation-Contraction Coupling and Excitable Cells Using Impedance Based Systems with Millisecond Time Resolution In force · Medium confidence | Agilent Technologies, Inc. | In force | Medium confidence | ||
| US 10,533,985 | Label-Free Monitoring of Excitation-Contraction Coupling and Excitable Cells Using Impedance Based Systems with Millisecond Time Resolution In force · Medium confidence | Agilent Technologies, Inc. | In force | Medium confidence | ||
| US 11,360,072 | Label-Free Monitoring of Excitation-Contraction Coupling and Excitable Cells Using Impedance Based Systems with Millisecond Time Resolution In force · Medium confidence | Agilent Technologies, Inc. | In force | Medium confidence | ||
| US 11,906,508 | Label-Free Monitoring of Excitation-Contraction Coupling and Excitable Cells Using Impedance Based Systems with Millisecond Time Resolution In force · High confidence | Agilent Technologies, Inc. | In force | High confidence | ||
| US 9,612,234 | Data Analysis of Impedance-Based Cardiomyocyte-Beating Signals as Detected on Real-Time Cell Analysis (RTCA) Cardio Instruments In force · Medium confidence | Agilent Technologies, Inc. | In force | Medium confidence | ||
| US 9,709,548 | Label-Free Monitoring of Excitation-Contraction Coupling and Excitable Cells Using Impedance Based Systems with Millisecond Time Resolution In force · Medium confidence | Agilent Technologies, Inc. | In force | Medium confidence | ||
| US 8,921,041 | Device and Method for Electroporation-Based Delivery of Molecules into Cells and Dynamic Monitoring of Cell Responses Lapsed Dec 30, 2022 on the fee record Ended Dec 30, 2022 · Medium confidence | Agilent Technologies, Inc. | Lapsed Dec 30, 2022 on the fee record | Ended Dec 30, 2022 | Medium confidence | |
| US 10,067,121 | Dynamic Montioring of G-Protein Coupled Receptor (GPCR) and Receptor Tyrosine Kinase (RTK) Activity and Pathways in Living Cells Using Real-Time Microelectronic Cell Sensing Technology Term ended · USPTO later recorded non-payment Oct 12, 2026 Term ended Jul 18, 2023 · Medium confidence | Agilent Technologies, Inc. | Term ended USPTO later recorded non-payment Oct 12, 2026 | Term ended Jul 18, 2023 | Medium confidence | |
| US 10,168,318 | A Method of Measuring Cell-Substrate Impedance in Living Cells to Identify Compounds Affecting Receptor Tyrosine Kinase (RTK) Activity and Pathways Term ended Ended no later than Jul 18, 2023 · Medium confidence | Agilent Technologies, Inc. | Term ended | Ended no later than Jul 18, 2023 | Medium confidence | |
| 29 more patents in this group · Pro | ||||||
10 of 39 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 39, including 26 expired.
7 of these are in force and held by Agilent Technologies, Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.